Russia has started clinical use of a personalized vaccine for colorectal cancer patients, Igor Borisevich, deputy head of the Federal Medical and Biological Agency (FMBA), announced on November 18.
The Oncopept vaccine is a peptide-based treatment. It is customized for each patient by targeting the specific genetic characteristics of their tumor. This process aims to train the immune system to identify and attack cancer cells.
Oncopept enters clinical use
Borisevich presented the vaccine at the Innovative Practice: Science Plus Business congress. He said the drug is developed, registered, and has officially entered clinical use. Borisevich told the session that recruitment for the treatment is ongoing.
The first patients received the Oncopept peptide vaccine in March. According to Izvestia, the drug is for adults who have undergone surgery. These patients must have also received at least two lines of systemic chemotherapy.
Veronika Skvortsova, the head of the FMBA, said the initial patients responded well to the vaccine. Skvortsova stated that no serious side effects were observed during the first follow-up period. The drug was producing the necessary immune response.

Researchers identified specific mutations to act as “identifiers” for cancer cells. Skvortsova said researchers used these identifiers to create a personalized peptide set. This set consists of short protein fragments. When these peptides are introduced into a patient’s body, they help the immune system learn to identify and destroy tumor cells. This action triggers a targeted anti-cancer response, Skvortsova said
Manufacturers tailor each dose
The vaccine is tailored to the unique tumor of each patient. Because of this, it cannot be shared between individuals. The FMBA reports the production process for one dose of Oncopept takes about 49 days. This includes at least seven days for quality control.
The clinical application of Oncopept follows earlier developments in Russian personalized medicine. De Último Minuto notes the Russian Health Ministry also provided clinical use permission for Neooncovac. This is an mRNA-based vaccine for advanced melanoma. Permission was granted as of November 20, 2025.
Interest in these personalized treatments is high. The FMBA released information in April showing the agency received 543 applications for use. This resulted in 24 patients being selected for treatment.

Oncology expert Evgeny Cheremushkin said on April 1 that these domestically developed vaccines are created individually for each tumor. He said they may eventually be available for free under compulsory medical insurance.
Neooncovac shows early results
Oncopept targets colorectal cancer, but the Neooncovac program focuses on melanoma. Alexander Gintsburg leads the Neooncovac vaccine program. He is the scientific director of Moscow’s Gamaleya National Research Center of Epidemiology and Microbiology. According to Gintsburg, six patients have received the Neooncovac vaccine to date.
The first patient treated with the experimental vaccine has been in complete remission for about four months. Gintsburg said in an interview with Gazeta.ru that recent medical examinations showed no new tumor formations. The patient’s previously detected metastases had disappeared.
A second patient is halfway through a course of 10 injections. This patient has reportedly tolerated the treatment better than the first patient. Doctors will monitor these patients for three years to ensure remission stability and watch for recurrence.
Medical professionals expect to treat 20 patients with this vaccine by the end of 2026. These initial findings are preliminary. They do not prove the vaccine is effective for a larger population. Clinical monitoring is required to evaluate long-term results and safety.
Cancer vaccines advance globally
The move toward personalized vaccines mirrors breakthroughs in international clinical trials. Merck & Co. and Moderna presented results from a phase III trial at the ESMO meeting in October. This trial studied a personalized neoantigen-based cancer vaccine. The trial involved nearly 1,140 patients with completely resected stage IIB–IV melanoma.
Researchers are looking for answers about which neoantigens drive effective T-cell responses. They also want to know what specific types of T cells are induced. There is enthusiasm for mRNA-based RNA vaccines. However, some researchers said it is not yet clear if they are superior to high-quality peptide vaccines. The two types have not been compared directly in a clinical setting.
The history of this field includes various attempts. Lloyd Old reported in 1959 that the BCG vaccine for tuberculosis could extend the survival of mice with cancer. Dendreon’s cell-based sipuleucel-T (Provenge) for prostate cancer arrived on the market in 2010.

Earlier attempts also occurred. GSK pursued a vaccine against the cancer-testis antigen MAGE-A3 over two decades ago. That attempt failed during phase III trials in 2013 and 2014. Modern mRNA technology may overcome previous limitations through multiplexing. This allows researchers to target more than one tumor-associated antigen at a time.
Doctors evaluate treatment success
Medical professionals like Nguyen Duy Anh use specific levels of response to evaluate cancer treatments. He is a physician and master’s degree holder. A complete response occurs when the cancer lesion disappears. A partial response means the lesion size has decreased. Disease stabilization occurs when the tumor shows no signs of progression.
New vaccine therapies offer hope for patients who have not responded to conventional regimens. But Dr. Duy Anh said current medicine cannot yet completely cure stage 4 cancer. Immunotherapy and targeted therapies can help many patients with lung, breast, or colorectal cancer. These treatments can maintain stable disease and quality of life for two to five years.
Large-scale multicenter studies and official validation from international health agencies are required for these vaccine protocols to become standard. Health experts say patients can still take proactive steps through established preventative measures. This includes using the Hepatitis B vaccine to reduce liver cancer risk. The HPV vaccine can prevent cervical cancer and other HPV-related cancers.
“Everybody's pursuing a very one-track focus,” says Stacey Adam, Chief Clinical Officer at the Foundation for the NIH (FNIH).
The work of the agency reflects its long history of managing specialized medical challenges, as the Federal Medical and Biological Agency was created in 2004. It serves as the legal successor to the 3rd Main Directorate of the USSR Ministry of Health.
The agency provides medical and sanitary support for workers in industries with particularly hazardous conditions, including those involved in space flights, diving, and caisson work. It also manages medical support for athletes on Russian national sports teams and oversees the safety of donor blood.
Dr. Duy Anh recommends that people prioritize regular health check-ups and appropriate screenings. He says following the guidance of qualified healthcare professionals can aid in early disease detection and risk reduction.